- Home
- YOSH vs PTIX Comparison
YOSH vs PTIX Comparison
Compare YOSH & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- PTIX
- Stock Information
- Founded
- YOSH 2016
- PTIX 1994
- Country
- YOSH United States
- PTIX United States
- Employees
- YOSH N/A
- PTIX N/A
- Industry
- YOSH Restaurants
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- PTIX Health Care
- Exchange
- YOSH Nasdaq
- PTIX Nasdaq
- Market Cap
- YOSH 4.5M
- PTIX 3.7M
- IPO Year
- YOSH 2022
- PTIX 2016
- Fundamental
- Price
- YOSH $3.49
- PTIX $0.44
- Analyst Decision
- YOSH
- PTIX
- Analyst Count
- YOSH 0
- PTIX 0
- Target Price
- YOSH N/A
- PTIX N/A
- AVG Volume (30 Days)
- YOSH 22.1K
- PTIX 377.2K
- Earning Date
- YOSH 11-19-2024
- PTIX 11-14-2024
- Dividend Yield
- YOSH N/A
- PTIX N/A
- EPS Growth
- YOSH N/A
- PTIX N/A
- EPS
- YOSH N/A
- PTIX N/A
- Revenue
- YOSH $11,652,880.00
- PTIX N/A
- Revenue This Year
- YOSH N/A
- PTIX N/A
- Revenue Next Year
- YOSH N/A
- PTIX N/A
- P/E Ratio
- YOSH N/A
- PTIX N/A
- Revenue Growth
- YOSH 25.97
- PTIX N/A
- 52 Week Low
- YOSH $2.71
- PTIX $0.43
- 52 Week High
- YOSH $8.25
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- YOSH 52.84
- PTIX 39.26
- Support Level
- YOSH $2.71
- PTIX $0.43
- Resistance Level
- YOSH $3.62
- PTIX $0.52
- Average True Range (ATR)
- YOSH 0.20
- PTIX 0.05
- MACD
- YOSH 0.07
- PTIX -0.01
- Stochastic Oscillator
- YOSH 85.79
- PTIX 6.74
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.